Next Article in Journal
Stable Isotope Tracing Metabolomics to Investigate the Metabolic Activity of Bioactive Compounds for Cancer Prevention and Treatment
Previous Article in Journal
MR1-Restricted T Cells in Cancer Immunotherapy
Open AccessArticle

Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib

Division of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate 028-3695, Japan
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(8), 2146; https://doi.org/10.3390/cancers12082146
Received: 26 June 2020 / Revised: 25 July 2020 / Accepted: 31 July 2020 / Published: 3 August 2020
(This article belongs to the Section Cancer Therapy)
Although sarcopenia is characterized by a loss of muscle strength and skeletal muscle mass, few studies have evaluated the effect of muscle strength on hepatocellular carcinoma (HCC) patients. We evaluated the impact of sarcopenia-related factors (grip strength (GS) and the skeletal muscle index (SMI)) on the survival among lenvatinib-treated unresectable HCC (u-HCC) patients. This single-center cohort study was conducted at a university hospital. The study population included 63 lenvatinib-treated u-HCC patients managed between April 2018 and April 2020. A decreased GS and decreased SMI were found in 21 (33.3%) and 22 (34.9%) patients, respectively. The overall survival (OS) of the normal GS group was significantly higher than that of the decreased GS group, while that of the normal and decreased SMI groups did not differ markedly. There were no significant differences in the progression-free survival between the normal GS and decreased GS groups or the normal SMI and decreased SMI groups. A multivariate Cox proportional hazards model showed that modified albumin-bilirubin-grade (mALBI) 2b (hazard ratio (HR) 4.39) and a decreased GS (HR 3.55) were independently associated with an increased risk of poor prognosis. In addition to the hepatic functional reserve, a decreased GS was a poor prognostic factor in lenvatinib-treated u-HCC patients. View Full-Text
Keywords: sarcopenia; grip strength; skeletal muscle index; hepatocellular carcinoma; lenvatinib; modified albumin-bilirubin grade sarcopenia; grip strength; skeletal muscle index; hepatocellular carcinoma; lenvatinib; modified albumin-bilirubin grade
Show Figures

Graphical abstract

MDPI and ACS Style

Endo, K.; Kuroda, H.; Kanazawa, J.; Sato, T.; Fujiwara, Y.; Abe, T.; Sato, H.; Kooka, Y.; Oikawa, T.; Sawara, K.; Takikawa, Y. Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib. Cancers 2020, 12, 2146.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop